Opinion
Video
Author(s):
Paul E. Dato, MD, discusses how treatment selection between triplet therapy, doublet therapy, or androgen deprivation monotherapy should be based on disease volume, risk factors, patient age, fitness for chemotherapy, and patient preferences through shared decision-making.
Clinical Brief: Personalizing Treatment Selection in Metastatic Prostate Cancer
Main Discussion Topics
Key Points for Physicians
Notable Insights
The presenter acknowledges that chemotherapy is not an easy treatment to endure and emphasizes the importance of helping patients understand the clinical rationale and benefits to make the best personal decision.
Clinical Significance
Treatment selection in metastatic prostate cancer requires balancing objective disease characteristics with patient-specific factors through shared decision-making to optimize both clinical outcomes and quality of life.